Bio-Rad Laboratories (BIO) Cash & Current Investments (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Cash & Current Investments for 18 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Current Investments rose 17.81% year-over-year to $1.6 billion in Q2 2026; TTM through Jun 2026 was $1.6 billion, a 17.81% increase from a year earlier, with the FY2025 full-year figure at $1.5 billion, down 7.44% from the prior year.
• Cash & Current Investments was $1.6 billion for Q2 2026 at Bio-Rad Laboratories, up from $1.6 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $2.1 billion in Q1 2022 and troughed at $1.4 billion in Q2 2025.
• A 5-year average of $1.7 billion and a median of $1.7 billion in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments surged 105.84% in 2022 and declined 14.99% in 2025, its largest moves.
• Over 5 years, Cash & Current Investments stood at $1.8 billion in 2022, then fell by 10.25% to $1.6 billion in 2023, then gained by 3.57% to $1.7 billion in 2024, then declined by 7.44% to $1.5 billion in 2025, then advanced by 5.05% to $1.6 billion in 2026.
• The last three Cash & Current Investments figures came in at $1.6 billion (Q2 2026), $1.6 billion (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.